Literature DB >> 24435983

Comment on Williams NH, et al.: a systematic review and meta-analysis of biological treatments targeting tumour necrosis factor α for sciatica (Eur Spine J, 2013;22(9):1921-35).

Jing Wang1, Gui-tao Li, Hong-tao Sun.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24435983      PMCID： PMC3960419          DOI： 10.1007/s00586-014-3166-5

Source DB:  PubMed          Journal:  Eur Spine J        ISSN： 0940-6719            Impact factor:   3.134


× No keyword cloud information.
  3 in total

1.  Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up.

Authors:  Timo Korhonen; Jaro Karppinen; Antti Malmivaara; Reijo Autio; Jaakko Niinimäki; Leena Paimela; Eero Kyllönen; Karl-August Lindgren; Osmo Tervonen; Seppo Seitsalo; Heikki Hurri
Journal:  Spine (Phila Pa 1976)       Date:  2004-10-01       Impact factor: 3.468

2.  Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica.

Authors:  Jaro Karppinen; Timo Korhonen; Antti Malmivaara; Leena Paimela; Eero Kyllönen; Karl-August Lindgren; Pekka Rantanen; Osmo Tervonen; Jaakko Niinimäki; Seppo Seitsalo; Heikki Hurri
Journal:  Spine (Phila Pa 1976)       Date:  2003-04-15       Impact factor: 3.468

Review 3.  A systematic review and meta-analysis of biological treatments targeting tumour necrosis factor α for sciatica.

Authors:  Nefyn H Williams; Ruth Lewis; Nafees Ud Din; Hosam E Matar; Deborah Fitzsimmons; Ceri J Phillips; Alex Sutton; Kim Burton; Maggie Hendry; Sadia Nafees; Clare Wilkinson
Journal:  Eur Spine J       Date:  2013-03-26       Impact factor: 3.134
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.